zumilokibart
Coverage of zumilokibart in the Nexus archive.
- AbbVie is buying an eczema and asthma drug developer for almost $11 billion
AbbVie is acquiring a drug developer for nearly $11 billion in cash to gain access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis.
- STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash, valuing the company at $135.11 per share, a 50% premium over its previous closing price. The deal focuses on Apogee's lead drug, zumilokibart, which targets IL-13 and is being tested for inflammatory diseases like atopic dermatitis and asthma.
- STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
The FDA delayed a decision on AstraZeneca's breast cancer drug camizestrant due to advisory concerns over its trial design. Blackstone Life Sciences is investing $1.3 billion in Apogee Therapeutics for Phase 3 development of zumilokibart, a long-acting atopic dermatitis treatment. Kailera's experimental obesity drug, targeting three hormones, showed significant weight loss in a Phase 1 study.